NASDAQ:CFMS Conformis - CFMS Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Conformis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $2.62 +0.06 (+2.34%) (As of 02/3/2023 12:00 AM ET) Add Compare Share Share Today's Range$2.59▼$2.8050-Day Range$2.31▼$3.7852-Week Range$1.20▼$18.77Volume44,218 shsAverage Volume37,952 shsMarket Capitalization$19.70 millionP/E RatioN/ADividend YieldN/APrice Target$4.50 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Conformis MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside71.8% Upside$4.50 Price TargetShort InterestHealthy0.99% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($8.32) to ($5.43) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.29 out of 5 starsMedical Sector332nd out of 1,029 stocksSurgical Appliances & Supplies Industry9th out of 23 stocks 3.5 Analyst's Opinion Consensus RatingConformis has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $4.50, Conformis has a forecasted upside of 71.8% from its current price of $2.62.Amount of Analyst CoverageConformis has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.99% of the float of Conformis has been sold short.Short Interest Ratio / Days to CoverConformis has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Conformis has recently decreased by 11.18%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldConformis does not currently pay a dividend.Dividend GrowthConformis does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CFMS. Previous Next 2.6 News and Social Media Coverage News SentimentConformis has a news sentiment score of 0.70. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.47 average news sentiment score of Medical companies.Search Interest4 people have searched for CFMS on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Conformis to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Conformis insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.70% of the stock of Conformis is held by insiders. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Conformis are expected to grow in the coming year, from ($8.32) to ($5.43) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Conformis is -0.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Conformis is -0.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioConformis has a P/B Ratio of 0.19. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Conformis (NASDAQ:CFMS) StockConforMIS, Inc. is a medical technology company, which engages in the development, manufacture, and sale of joint replacement implants. It operates through the following geographical segments: United States, Germany, and Rest of the World. The firm's products include iUni, iDuo, iTotal CR, and iTotal. The company was founded by Philipp Lang in 2004 and is headquartered in Billerica, MA.Read More Receive CFMS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Conformis and its competitors with MarketBeat's FREE daily newsletter. Email Address CFMS Stock News HeadlinesJanuary 23, 2023 | finance.yahoo.comConformis, Inc. to Announce Financial Results for Its Fourth Quarter and Full-Year 2022January 4, 2023 | finance.yahoo.comConformis, Inc. (CFMS) Stock Historical Prices & Data - Yahoo FinanceFebruary 4, 2023 | Wall Street Watch Dogs (Ad)A gold storm is coming…“We are in the early stages of a mania – the calm before the storm.”...November 30, 2022 | finance.yahoo.comConformis, Inc. Regains Compliance with Nasdaq’s Minimum Bid Price RuleNovember 29, 2022 | finance.yahoo.comConformis Announces First Procedure Performed Using New Actera™ Hip SystemNovember 17, 2022 | finance.yahoo.comConformis Announces Full Commercial Launch of Imprint™November 15, 2022 | finance.yahoo.comConformis, Inc. Announces Settlement of Medacta Patent LitigationNovember 11, 2022 | finance.yahoo.comConformis, Inc.'s (NASDAQ:CFMS) 48% loss last week hit both individual investors who own 52% as well as institutionsFebruary 4, 2023 | Wall Street Watch Dogs (Ad)A gold storm is coming…“We are in the early stages of a mania – the calm before the storm.”...November 9, 2022 | finance.yahoo.comConformis, Inc. Effects 1-for-25 Reverse Stock SplitNovember 2, 2022 | finance.yahoo.comConformis Reports Third Quarter 2022 Financial ResultsOctober 5, 2022 | globenewswire.comConformis, Inc. to Announce Financial Results for Its Third Quarter 2022 - GlobeNewswireOctober 5, 2022 | finance.yahoo.comConformis, Inc. to Announce Financial Results for Its Third Quarter 2022October 2, 2022 | reuters.comCFMS.O - ConforMIS Inc | Stock Price & Latest News | ReutersSeptember 14, 2022 | au.investing.comAfter-Hours Movers: Starbucks Gains On Outlook, Flowserve Falls...September 14, 2022 | investing.comPre-Open Movers: Tech Stocks Lift After Drubbing, Block Falls on DowngradeSeptember 14, 2022 | benzinga.comConformis (NASDAQ:CFMS), BRP (NASDAQ:DOOO) – BRP, Conformis And 3 Stocks To Watch Heading Into Wednesday - BenzingaSeptember 13, 2022 | investing.comAfter-Hours Movers: Starbucks Gains On Outlook, Flowserve Falls on Higher Costs By Investing.com - Investing.comSeptember 13, 2022 | benzinga.comConformis (NASDAQ:CFMS) – Conformis Actera Hip System Receives 510(k) Clearance From The U.S. FDA - BenzingaSeptember 13, 2022 | seekingalpha.comConformis stock jumps 17% aftermarket on FDA 510(k) clearance for Actera hip system - Seeking AlphaSeptember 13, 2022 | benzinga.comConformis (NASDAQ:CFMS) – Conformis Shares Shoot Higher Following FDA Clearance For Actera Hip System - BenzingaSeptember 13, 2022 | globenewswire.comConformis Actera™ Hip System Receives 510(k) Clearance from the U.S. Food and Drug Administration - GlobeNewswireSeptember 13, 2022 | finance.yahoo.comConformis Actera™ Hip System Receives 510(k) Clearance from the U.S. Food and Drug AdministrationSeptember 13, 2022 | finance.yahoo.comConformis, Inc. (CFMS)September 12, 2022 | thestreet.comHere's Why ConforMIS (CFMS) Stock is Tanking TodayAugust 31, 2022 | msn.comConformis's Return On Capital Employed InsightsAugust 30, 2022 | benzinga.comConformis, Inc. to Participate in the H.C. Wainwright & Co. 24th Annual Global Investment Conference - BenzingaSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive CFMS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Conformis and its competitors with MarketBeat's FREE daily newsletter. Email Address CFMS Company Calendar Last Earnings11/03/2021Today2/04/2023Next Earnings (Confirmed)3/01/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical appliances & supplies Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CFMS CUSIPN/A CIK1305773 Webwww.conformis.com Phone(781) 345-9001Fax781-345-0147Employees310Year FoundedN/APrice Target and Rating Average Stock Price Forecast$4.50 High Stock Price Forecast$8.00 Low Stock Price Forecast$1.00 Forecasted Upside/Downside+71.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($8.75) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-2,410,000.00 Net Margins-104.46% Pretax Margin-104.45% Return on Equity-78.14% Return on Assets-50.59% Debt Debt-to-Equity Ratio0.33 Current Ratio5.07 Quick Ratio4.04 Sales & Book Value Annual Sales$99.86 million Price / Sales0.20 Cash Flow$0.26 per share Price / Cash Flow10.24 Book Value$13.51 per share Price / Book0.19Miscellaneous Outstanding Shares7,520,000Free Float7,239,000Market Cap$19.70 million OptionableNot Optionable Beta1.03 Key ExecutivesMark A. AugustiPresident, Chief Executive Officer & DirectorMichael FillionChief Operating OfficerRobert S. HoweCFO, Treasurer & Principal Accounting OfficerJohn SlaminChief Technology OfficerMarc QuartulliVice President-Clinical Affairs & Market AccessKey CompetitorsSientraNASDAQ:SIENHeart Test LaboratoriesNASDAQ:HSCSEargoNASDAQ:EARSurgalignNASDAQ:SRGAInvacareNYSE:IVCView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 8,191 shares on 12/8/2022Ownership: 4.894%Vanguard Group Inc.Sold 703,073 shares on 11/15/2022Ownership: 98.282%Bank of New York Mellon CorpBought 8,191 shares on 11/15/2022Ownership: 4.894%Renaissance Technologies LLCBought 188,200 shares on 11/14/2022Ownership: 63.372%MYDA Advisors LLCBought 697,404 shares on 11/10/2022Ownership: 0.371%View All Insider TransactionsView All Institutional Transactions CFMS Stock - Frequently Asked Questions Should I buy or sell Conformis stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Conformis in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CFMS shares. View CFMS analyst ratings or view top-rated stocks. What is Conformis' stock price forecast for 2023? 2 analysts have issued 12 month target prices for Conformis' stock. Their CFMS share price forecasts range from $1.00 to $8.00. On average, they predict the company's stock price to reach $4.50 in the next twelve months. This suggests a possible upside of 71.8% from the stock's current price. View analysts price targets for CFMS or view top-rated stocks among Wall Street analysts. How have CFMS shares performed in 2023? Conformis' stock was trading at $3.32 at the beginning of the year. Since then, CFMS stock has decreased by 21.1% and is now trading at $2.62. View the best growth stocks for 2023 here. When is Conformis' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 1st 2023. View our CFMS earnings forecast. How can I listen to Conformis' earnings call? Conformis will be holding an earnings conference call on Wednesday, March 1st at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link. How were Conformis' earnings last quarter? Conformis, Inc. (NASDAQ:CFMS) issued its quarterly earnings data on Wednesday, November, 3rd. The medical instruments supplier reported ($0.07) EPS for the quarter, meeting analysts' consensus estimates of ($0.07). The medical instruments supplier earned $14.25 million during the quarter, compared to the consensus estimate of $14.08 million. Conformis had a negative net margin of 104.46% and a negative trailing twelve-month return on equity of 78.14%. During the same period in the previous year, the firm earned ($0.09) EPS. What guidance has Conformis issued on next quarter's earnings? Conformis issued an update on its fourth quarter 2022 earnings guidance on Wednesday, November, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $13.00 million-$14.00 million, compared to the consensus revenue estimate of $15.99 million. What is Mark Augusti's approval rating as Conformis' CEO? 15 employees have rated Conformis Chief Executive Officer Mark Augusti on Glassdoor.com. Mark Augusti has an approval rating of 55% among the company's employees. This puts Mark Augusti in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Conformis own? Based on aggregate information from My MarketBeat watchlists, some companies that other Conformis investors own include Advanced Micro Devices (AMD), Martin Midstream Partners (MMLP), Micron Technology (MU), NVIDIA (NVDA), Trevena (TRVN), Cisco Systems (CSCO), Pfizer (PFE), AbbVie (ABBV), Alibaba Group (BABA) and AT&T (T). When did Conformis IPO? (CFMS) raised $135 million in an initial public offering on Wednesday, July 1st 2015. The company issued 9,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan and Deutsche Bank Securities acted as the underwriters for the IPO and Wells Fargo Securities and Canaccord Genuity were co-managers. What is Conformis' stock symbol? Conformis trades on the NASDAQ under the ticker symbol "CFMS." Who are Conformis' major shareholders? Conformis' stock is owned by a variety of retail and institutional investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include J Brent Alldredge, Kenneth P Fallon III, Mark A Augusti, Mark A Augusti and Robert S Howe. View institutional ownership trends. How do I buy shares of Conformis? Shares of CFMS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Conformis' stock price today? One share of CFMS stock can currently be purchased for approximately $2.62. How much money does Conformis make? Conformis (NASDAQ:CFMS) has a market capitalization of $19.70 million and generates $99.86 million in revenue each year. The medical instruments supplier earns $-2,410,000.00 in net income (profit) each year or ($8.75) on an earnings per share basis. How many employees does Conformis have? The company employs 310 workers across the globe. How can I contact Conformis? Conformis' mailing address is 600 TECHNOLOGY PARK DRIVE, BILLERICA MA, 01821. The official website for the company is www.conformis.com. The medical instruments supplier can be reached via phone at (781) 345-9001, via email at ir@conformis.com, or via fax at 781-345-0147. This page (NASDAQ:CFMS) was last updated on 2/4/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.